DOLUTEGRAVIR\RILPIVIRINE: 1,216 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
1,216
Total FAERS Reports
73 (6.0%)
Deaths Reported
176
Hospitalizations
1,216
As Primary/Secondary Suspect
34
Life-Threatening
15
Disabilities
Active Ingredient: DOLUTEGRAVIR SODIUM\RILPIVIRINE HYDROCHLORIDE ·
First Report: 19730519 · Latest Report: 20250909
What Are the Most Common DOLUTEGRAVIR\RILPIVIRINE Side Effects?
#1 Most Reported
Product dose omission issue
281 reports (23.1%)
#2 Most Reported
Fatigue
53 reports (4.4%)
#3 Most Reported
Product use issue
51 reports (4.2%)
All DOLUTEGRAVIR\RILPIVIRINE Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Product dose omission issue | 281 | 23.1% | 1 | 4 |
| Fatigue | 53 | 4.4% | 4 | 2 |
| Product use issue | 51 | 4.2% | 7 | 3 |
| Death | 47 | 3.9% | 45 | 2 |
| Rash | 46 | 3.8% | 4 | 7 |
| Viral load increased | 45 | 3.7% | 0 | 5 |
| Diarrhoea | 42 | 3.5% | 0 | 7 |
| Weight increased | 40 | 3.3% | 0 | 1 |
| Headache | 38 | 3.1% | 4 | 0 |
| Nausea | 34 | 2.8% | 1 | 1 |
| Condition aggravated | 33 | 2.7% | 2 | 7 |
| Depression | 33 | 2.7% | 0 | 2 |
| Drug ineffective | 33 | 2.7% | 4 | 2 |
| Drug interaction | 33 | 2.7% | 0 | 17 |
| Hypertension | 29 | 2.4% | 4 | 10 |
| Pathogen resistance | 29 | 2.4% | 0 | 6 |
| Hospitalisation | 27 | 2.2% | 1 | 25 |
| Pain | 26 | 2.1% | 3 | 0 |
| Viral mutation identified | 26 | 2.1% | 0 | 6 |
| Insomnia | 25 | 2.1% | 0 | 2 |
Who Reports DOLUTEGRAVIR\RILPIVIRINE Side Effects? Age & Gender Data
Gender: 26.5% female, 73.5% male. Average age: 53.8 years. Most reports from: US. View detailed demographics →
Is DOLUTEGRAVIR\RILPIVIRINE Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2004 | 6 | 0 | 0 |
| 2010 | 1 | 0 | 0 |
| 2014 | 6 | 0 | 6 |
| 2015 | 8 | 1 | 1 |
| 2016 | 8 | 0 | 2 |
| 2017 | 7 | 1 | 1 |
| 2018 | 67 | 1 | 8 |
| 2019 | 99 | 3 | 19 |
| 2020 | 40 | 3 | 11 |
| 2021 | 41 | 2 | 14 |
| 2022 | 69 | 6 | 11 |
| 2023 | 96 | 16 | 5 |
| 2024 | 105 | 12 | 10 |
| 2025 | 44 | 3 | 3 |
What Is DOLUTEGRAVIR\RILPIVIRINE Used For?
| Indication | Reports |
|---|---|
| Hiv infection | 556 |
| Product used for unknown indication | 502 |
| Antiretroviral therapy | 18 |
| Hiv infection cdc group iii | 12 |
| Hiv test positive | 10 |
| Acquired immunodeficiency syndrome | 9 |
| Hiv test | 9 |
| Hiv carrier | 7 |
DOLUTEGRAVIR\RILPIVIRINE vs Alternatives: Which Is Safer?
DOLUTEGRAVIR\RILPIVIRINE vs DOMPERIDONE
DOLUTEGRAVIR\RILPIVIRINE vs DOMPERIDONE\PANTOPRAZOLE
DOLUTEGRAVIR\RILPIVIRINE vs DONANEMAB-AZBT
DOLUTEGRAVIR\RILPIVIRINE vs DONEPEZIL
DOLUTEGRAVIR\RILPIVIRINE vs DONEPEZIL\DONEPEZIL
DOLUTEGRAVIR\RILPIVIRINE vs DONEPEZIL\MEMANTINE
DOLUTEGRAVIR\RILPIVIRINE vs DONEPEZIL\OMEPRAZOLE\OMEPRAZOLE
DOLUTEGRAVIR\RILPIVIRINE vs DONOR HUMAN STOOL
DOLUTEGRAVIR\RILPIVIRINE vs DOPAMINE
DOLUTEGRAVIR\RILPIVIRINE vs DOPAMINE\DOPAMINE
Official FDA Label for DOLUTEGRAVIR\RILPIVIRINE
Official prescribing information from the FDA-approved drug label.